Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA

Kodiak Sciences Inc.

Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).
85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); no intraocular inflammation.
DAYBREAK Phase 3 wet AMD study fully enrolled (690 subjects); topline expected Sept 2026.
Q4 2025 net loss $56.7M ($1.04/shr); cash $209.9M; Dec 2025 equity raise net $173M.
KSI-101 Phase 3 PEAK topline 4Q2026, PINNACLE 2Q2027; Phase 1b APEX data showed robust responses.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights.

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-134854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.